drugset

drugset / Trial / NCT00303199

Study of ZIO-101 in Multiple Myeloma

NCT00303199 ↗

Phase 1/2 Completed 35 enrolled Alaunos Therapeutics

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma

Timeline

Start: 2006-01
Primary completion: 2007-08
Completion: 2007-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Darinaparsin	Small molecule	—	Intravenous

Indications